Clinical Trials

After rigorous testing in animal models, new diagnostics and therapeutics discovered by BCC researchers enter into early-phase clinical trials (phases I, II, and III), which screen for safety and efficacy in humans. A strong clinical trials program at the JGBCC ensures that Kentuckians have access to cutting-edge anti-cancer agents without having to leave the state.

Our clinical trials program for cancer patients has achieved national recognition as a major trial site for large pharmaceutical companies including Genentech, Amgen, Bristol Myers Squibb and Merck as well as the National Cancer Institute (NCI).  On average, we have over 100 open clinical trials and 750 cancer patients actively participating in clinical research.  Our Cancer Center along with Moffitt Cancer Center were the top two accruing sites for the largest ever NCI-sponsored trial for head & neck patients, RTOG0522 which tested the efficacy of an anti-EGFR cetuximab, and, in 2014, Dr. Chesney's clinical research group and a group from Memorial Sloan Kettering Cancer Center were the top two accruing sites for a combination trial of two immunotherapies that demonstrated the greatest clinical efficacy ever observed for an immunotherapy regimen. Importantly, our clinical trialists are helping our scientists to translate basic discoveries into clinical benefits for our patients and are also making astute clinical observations that are leading to new ideas to test in our laboratories.

Clinical researchers include: Victor Van Berkel, Jason Chesney, Donald Miller, Kelly McMasters, Craig Silverman, Beth Riley, Nicholas Ajkay, Stacey Crawford, Mary Ann Sanders, Carrie Lenneman, Megan Nelson, Jarrod Little, Bradon Wilhelmi, Terry McCurry, Mary Hubert, Robert Martin, Rebecca Redman, Charles Scoggins, Vivek Sharma, Adam Rojan, Missy Potts, Prejesh Philips, Jeffrey Bumpous, Kevin Potts, Neal Dunlap, Liz Cash, Paul Tennant, Jamie Messer, Maxwell Boakye, Thomas Altstadt, Shiao Woo, Harig Nauta and Dan Metzinger.